Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Withdrawal of medications leads to worsening of OGTT parameters in youth with impaired glucose tolerance or recently‐diagnosed type 2 diabetes

Pediatric Diabetes(2020)10.1111/pedi.13129Source: DataRank Database

Withdrawal of medications leads to worsening of OGTT parameters in youth with impaired glucose tolerance or recently‐diagnosed type 2 diabetes is a research paper published in Pediatric Diabetes (2020). On theSindex it has a DataRank of 0.530. It has been cited 7 times, with 5 citing works in its 1-hop citation network.

N/A

0.530DataRank · unranked

Scored on demand from live citation data

Deposits data Open Access7 citations · 5 citing works in its network

Download PDF

Cite:

Linked data & code

nct

Data availability

Repositories this paper deposited data in (declared in PubMed).

ClinicalTrials.govNCT01779375

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (53 grants)Impact (FWCI 1.03)OA: greenTopics (37)IDs (PubMed, PMC, OpenAlex)Annotations (1)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

DataRank Breakdown

Base Score 59%Citation Network 41%

Base Score Contribution

0.312

From this paper's citation signal

Citation Network Contribution

0.218

From 5 citing papers with measurable signal

Learn more about DataRank methodology →

Top 5 citers driving the network score

Ranked by each citer's contribution to N(p) — log1p(C_q) divided by its reference count — out of 5 citers.

Pediatric Type 2 Diabetes Presentation During the COVID-19 Pandemic
Clinical Pediatrics202115 citations19 referencesContributes 0.146
Considering metformin as a second-line treatment for children and adolescents with prediabetes
Journal of Pediatric Endocrinology and Metabolism20226 citations35 referencesContributes 0.056
Diabetic kidney disease in children and adolescents: an update
Pediatric Nephrology202121 citations99 referencesContributes 0.031
Metformin therapy in pediatric type 2 diabetes mellitus and its comorbidities: A review
Frontiers in Endocrinology202311 citations197 referencesContributes 0.013
Beta Cell Dysfunction in Youth- and Adult-Onset Type 2 Diabetes: An Extensive Narrative Review with a Special Focus on the Role of Nutrients
Nutrients202325 citations296 referencesContributes 0.011

Authors (61)

Sharon L. Edelstein ORCID,Silva Arslanian ORCID,Sonia Caprio ORCID,Philip Zeitler ORCID,Thomas A. Buchanan ORCID

Live enrichment

PubMed:32985775 PMC:PMC7642167 OpenAlex:https://openalex.org/W3088889304

National Institutes of Health

Grant: UL1‐TR‐001863

National Institutes of Health

Grant: UL1‐TR‐001858

National Institutes of Health

Grant: UL1‐TR‐001857

National Institutes of Health

Grant: UL1‐TR‐001855

National Institutes of Health

Grant: UL1‐TR‐001108

National Institutes of Health

Grant: UL1‐TR‐001082

National Institutes of Health

Grant: UL1‐TR‐000430

National Institutes of Health

Grant: P30‐DK‐097512

National Institutes of Health

Grant: P30‐DK‐045735

National Institutes of Health

Grant: P30‐DK‐020595

National Institutes of Health

Grant: P30‐DK‐017047

National Institutes of Health

Grant: U01‐DK‐094467

National Institutes of Health

Grant: U01‐DK‐094438

National Institutes of Health

Grant: U01‐DK‐094431

National Institutes of Health

Grant: U01‐DK‐094430

National Institutes of Health

Grant: U01‐DK‐094406

NIH HHS

Grant: P30-DK-017047

NCATS NIH HHS

Grant: TL1 TR001858

NIH HHS

Grant: P30-DK-020595

NIH HHS

Grant: P30-DK-045735

NIH HHS

Grant: U01-DK-094430

NIH HHS

Grant: U01-DK-094431

NCATS NIH HHS

Grant: UL1 TR001082

NCATS NIH HHS

Grant: UL1 TR001855

NIH HHS

Grant: UL1-TR-001082

NIH HHS

Grant: UL1-TR-001108

NIDDK NIH HHS

Grant: P30 DK097512

NIDDK NIH HHS

Grant: U01 DK094430

NIH HHS

Grant: U01-DK-094406

NIH HHS

Grant: U01-DK-094467

NCATS NIH HHS

Grant: UL1 TR001863

NIDDK NIH HHS

Grant: U01 DK094406

NIH HHS

Grant: U01-DK-094438

NCATS NIH HHS

Grant: UL1 TR001108

NIDDK NIH HHS

Grant: P30 DK017047

NIDDK NIH HHS

Grant: P30 DK020595

NIDDK NIH HHS

Grant: P30 DK045735

NCATS NIH HHS

Grant: UL1 TR001857

NIH HHS

Grant: UL1-TR-001857

NIH HHS

Grant: UL1-TR-001863

NHLBI NIH HHS

Grant: K24 HL145076

NIDDK NIH HHS

Grant: U01 DK094431

NIDDK NIH HHS

Grant: U01 DK094467

NIH HHS

Grant: UL1-TR-000430

NIH HHS

Grant: UL1-TR-001855

NIH HHS

Grant: P30-DK-097512

NIDDK NIH HHS

Grant: U01 DK094438

NCATS NIH HHS

Grant: UL1 TR000430

NIH HHS

Grant: UL1-TR-001858

Abbott Laboratories

Novo Nordisk

U.S. Department of Veterans Affairs

FWCI

1.03

Citation Percentile

0.8%

Citation Trend

2021

2022

2023

2024

greenLicense: http://doi.wiley.com/10.1002/tdm_license_1.1

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/7642167

publisherhttps://onlinelibrary.wiley.com/doi/pdf/10.1111/pedi.13129

publisherhttps://onlinelibrary.wiley.com/doi/full-xml/10.1111/pedi.13129

journalhttps://doi.org/10.1111/pedi.13129

Fields of Study

Obesity, Physical Activity, DietDiabetes Management and ResearchDiabetes Treatment and Management

MeSH Terms

AdolescentBlood GlucoseChildDiabetes Mellitus, Type 2FastingFemaleFollow-Up StudiesGlucose Tolerance TestHumansHypoglycemic AgentsInsulin ResistanceMaleMetforminGlucose IntoleranceYoung Adult

Keywords

MedicineMetforminInternal medicineType 2 diabetesImpaired glucose toleranceInsulinDiabetes mellitusEndocrinologyRandomized controlled trialGastroenterologyInsulin sensitivityMedicationPediatricinsulin secretionPrediabetesInsulin GlargineGlucose ToleranceΒ-cellInsulin Response

Sustainable Development Goals

SDG 0: Good health and well-being